PHOTO
Abu Dhabi: His Excellency Zaki Nusseibeh, Cultural Advisor to His Highness President of the United Arab Emirates, Chancellor of the United Arab Emirates University, witnessed a Memorandum of Understanding’s signing ceremony between the College of Medicine and Health Sciences in UAEU and G42 Healthcare, a subsidiary of the Abu Dhabi-based technology company Group 42 (G42), on 16th February 2021, which was attended by His Excellenecy Prof. Ghaleb Al Hadrami Al Breiki, Acting Vice Chancellor of UAEU and Mr. Ashish Koshy, Chief Executive Officer, G42 Healthcare.
Scientists and academicians from UAEU along with senior management from G42 Healthcare joined the dignitaries at Biogenix Labs - Omics Centre of Excellence, located in Masdar City, Abu Dhabi.
Commenting on this MoU, H.E. Zaki Nusseibeh said: “We are pleased with the collaboration between the United Arab Emirates University and G42 Healthcare on academic programs which will positively affect the local community and improve the healthcare sector and its infrastructure. Our researchers and scientists shall apply the most advanced and innovative technologies to lay the foundations for a healthier future for all members of society in the United Arab Emirates.”
H.E. Zaki Nusseibeh and the university delegation toured the center, where they were briefed on major projects around genomics, biobanking, molecular and biogenetic sequencing, future of multidisciplinary biological sciences, and major initiatives, such as Emirati Genome Program.
During the tour, the lab staff introduced them to the various stations such as Sample Management, Extraction, Quality Control (QC), Biobanking, Automation & R&D, Sample Preparation & Library Preparation, and Long & Short Read Sequencing. During the visit, H.E. Zaki Nusseibeh, and his team contributed to the Emirati Genome Program, one of the world’s most comprehensive genomics initiative, by donating their blood sample and motivated others to volunteer as well.
Mr. Ashish Koshy, CEO, G42 Healthcare commented, “As our organization grows at a rapid pace, collaboration is vital to capitalize on the collective wisdom and skillset of our researchers, scientists and academicians to create long lasting impactful healthcare solutions. Our partnership with the United Arab Emirates University will inspire dynamic and scalable innovations that will benefit the nation and its future generations.”
The United Arab Emirates University and G42 Healthcare have plans to expand their cooperation across several projects including researching on Emirati Genome Program, establishing COVID-19 research, and testing facility, genetic counseling, spearheading joint grant funding, facilitating student and faculty training, and initiating several educational and training programs. The MoU aims to exchange experiences, knowledge, and research between the two sides.
A key player in the fight against the global pandemic, G42 Healthcare leverages its expertise and technology to generate relevant and insightful data for a plethora of projects at the Omics Centre of Excellence.
-Ends-
About G42 Healthcare
G42 Healthcare, a subsidiary of Abu Dhabi-based Group 42 – a leading technology company, is committed to developing a world-class, sustainable healthcare sector in the UAE. At the forefront in the battle against COVID-19, G42 Healthcare uses its advanced AI techniques and vast computing resources to accelerate the detection of COVID-19, conduct research into new vaccines and drug therapies, and map trends in the outbreak including virus mutations. The company was responsible was conducting the world’s first phase III clinical trial of inactivated vaccines across the Pan Arab region with over 43,000 volunteers participating from over 125 nationalities.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.